The sputum saccharide chain antigen (Krebs von den Lungen-6 [KL-6])
| INTRODUC TI ON
Interstitial lung disease (ILD) is a group of diseases characterized by various forms of pulmonary interstitial inflammation and fibrosis, which are usually chronic, progressive, and fatal, 1 causing death 2-5 years after diagnosis in most patients. 2, 3 These disorders primarily affect the pulmonary interstitium, alveolar cavity, and bronchioles. 4 Presently, clinical diagnostic methods of ILD are extremely limited, including HRCT, pulmonary function test, bronchial lavage, lung biopsy, and other examinations, which require specific medical equipment and will lead to patient discomfort. 5 Therefore, it is necessary to find safe, simple, and reproducible biological markers for the prediction and early diagnosis of ILD. 6 Since the most important feature of ILD is repeated damage or repair of type II alveolar epithelial cells, Krebs von den Lungen-6 (KL-6) secreted by type II alveolar epithelial cells is highly regarded. 6, 7 When epithelial cells are damaged, KL-6 enters the circulation, promotes fibroblast proliferation and migration, inhibits apoptosis, and aggravates the development of pulmonary fibrosis. Therefore, KL-6 is considered the most accurate biomarker in the diagnosis of ILD. 8, 9 Studies have shown that, when KL-6 has a cutoff value of 500 U/ mL, it can distinguish among patients with ILD, healthy subjects, and those with other benign non-ILDs. 10 Enzyme-linked immunosorbent assay using an anti-KL-6 monoclonal antibody has been widely used in clinical laboratories. 11 Fully automated analyzers using various methodologies, such as chemiluminescent microparticle immunoassay (CMIA) or chemiluminescent enzyme immunoassay (CLEIA), for example, LUMIPULSE G1200 (Fujirebio Diagnostics), had been introduced and used clinically. Robust midsized fully automated chemiluminescence-based enzyme immune-analyzers and their analytical performances have been evaluated. 12, 13 Recently, Sysmex Corporation has released a newly developed KL-6 assay kit using the HISCL-5000 analyzer.
This study used the HISCL-5000 analyzer (hereinafter referred to as SYSTEM A) and LUMIPULSE G1200 analyzer (hereinafter referred to as SYSTEM B) to measure serum KL-6 levels in patients with ILD, lung cancer, and other respiratory diseases and healthy individuals. This study aimed to investigate the diagnostic value of serum KL-6 in ILD and evaluate the clinical performance of the HISCL-5000 analyzer. 
| MATERIAL S AND ME THODS

| Information of materials
| Patient enrollment criteria
| Measurement of KL-6 level
Blood collection was performed following a standard protocol.
Peripheral blood samples were collected from each patient using a vacuum blood vessel containing separating gel. After centrifuging for 10 minutes at 1000 × g, the upper layer was collected for testing.
Prior to testing, the serum was kept at room temperature for 30 minutes and was agitated in a vortex mixer. The serum fractions were aliquoted in 1.5 mL Eppendorf tubes and stored at 4°C until analysis.
Repeated freeze-thaw cycles were avoided.
We evaluated the basic performance of KL-6 assays using SYSTEM A, a fully automated immunochemistry analyzer that employs a CLEIA methodology with a two-step sandwich immunoassay. The primary antibody was biotin-binding anti-KL-6 mouse monoclonal antibody, and the secondary antibody was alkaline 
| Ethical approval
This study and the use of the human serum samples were approved by the Ethics Committee of The First Affiliated Hospital of Guangzhou Medical University (Ethics-[2017]-Reagents-35-02).
| Data analysis
Statistical analyses were conducted using Excel 2016 (Microsoft Excel ® 2016) and SPSS 22.0 (IBM Corp.). Parametric quantitative data were presented as mean ± standard deviation. Nonparametric quantitative data were presented as median (interquartile range).
Consistency between the two systems was evaluated using sensitivity, specificity, positive predictive value, negative predictive value, and kappa value. Disease diagnosis was used as the gold standard to establish the receiver operating characteristic (ROC) curve, and scatter plots and Bland-Altman plot were used to demonstrate the concentration distribution in the two methods. Correlation analyses for nonparametric data were performed using the Spearman tests, with the correlation coefficients presented as "r S ," and the closer the r S value is to −1 or +1, the stronger the correlation. And intraclass correlation coefficient (ICC) was used to evaluate the repeatability or consistency of the two systems. 
| RE SULTS
| Consistency and correlation between the two systems
The two systems simultaneously detected serum KL-6 index in the above-mentioned patients and performed consistency analysis.
With a cutoff value of 500 U/mL as the diagnostic threshold, the qualitative agreement rate of the two systems is 99.20%, and the sensitivity, specificity, and kappa value were 100%, 98.63%, and 0.984 (95% CI, 0.952-1.000), respectively ( Table 2) The difference in areas under the ROC curve between the two systems was 0.013, and the z-statistic was 1.772. The difference in diagnostic value between the two systems was not statistically significant (P = .0763). Note: Analyze the clinical diagnostic performance of the two analyzers with the exact diagnosis of the disease as a gold standard and compare the differences between the two analyzers. Abbreviations: AUC, area under the curve; CO, consistency; ILD, interstitial lung disease; NPV, negative predictive value; PPV, positive predictive value; SE, sensitivity; SP, specificity; SYSTEM A, LUMIPULSE G1200 analyzer; SYSTEM B, HISCL-5000 analyzer. Figure 4B ).
| Diagnostic performance of Kl-6 detected by SYSTEM A in ILD
| D ISCUSS I ON
In our study, we compared the KL-6 levels in 145 serum samples between SYSTEM A and SYSTEM B. The results showed that serum KL-6 in SYSTEM A had acceptable sensitivity and specificity and was comparable to that in SYSTEM B. Overall, we found a high degree of agreement among the two systems (agreement, 99.20%). Compared with SYSTEM B, SYSTEM A has a lower minimum detection limit (10 U/mL) and wider range of low detection values.
In this study, 56 patients who were diagnosed with ILD were selected. Other patients with lung cancer and other respiratory diseases, and healthy individuals were included for comparison.
With a cutoff level of 500 U/mL, the results showed that serum KL-6 levels in patients with ILD were significantly higher than those in other groups. Therefore, high serum KL-6 levels were useful in the adjunctive diagnosis of ILD. 15, 16 In our study, the diseases in the ILD group included connective tissue-associated interstitial pneumonia, autoimmune characteristics of interstitial pneumonia, idiopathic pulmonary fibrosis, vasculitis-related interstitial pneumonia, smoking-related interstitial pneumonia, and allergic reaction alveolitis. Using the recommended cutoff level (500 U/mL) in the monitoring system as reference, the patient's serum KL-6 test has a good positive rate. Due to the small sample size in some ILD subcategories, there is no difference in the KL-6 level in each of the subcategories (the result was not shown), and more cases need to be accumulated for further study. Although the KL-6 level does not distinguish the subtypes of ILD, KL-6 showed Because the cutoff value of the KL-6 level in patients with ILD was not determined, the correlation between KL-6 level and clinical activity of ILD was not obtained. In the next step, a multicentre largescale study can be conducted to refine the classification of patients with ILD, explore changes in KL-6 levels among subclass diseases, and design more rigorous experiments for further clarification.
| CON CLUS ION
The HISCL-5000 CLEIA system has a high diagnostic efficiency. The method can be applied to the quantitative detection of serum KL-6
in patients with respiratory diseases. Compared with those in other respiratory diseases, the serum KL-6 level in patients with ILD is significantly increased, suggesting that clinicians can use KL-6 in the auxiliary diagnosis of ILD. 
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